Trial Profile

A Prospective Study of Patients With B-Cell Hematologic Malignancies on Ibrutinib Therapy Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 09 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary)
Indications B-cell leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; COVID 2019 infections; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
Focus Adverse reactions

Most Recent Events

01 Dec 2021 Planned initiation date changed from 30 Jun 2021 to 1 Dec 2021.
01 Dec 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
20 Jan 2021 Planned initiation date changed from 31 Dec 2020 to 30 Jun 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com